The FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.

Grove AI, a company advancing the next generation of clinical trials with AI, today announced that it has been awarded the ...

A new study suggests Paxlovid may not reduce the risk of covid-19 hospitalizations and all-cause deaths in vaccinated adults ...

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...

Drugs in late-stage development may mean competition on price for two Pfizer medications that, by some accounts, are the most expensive cardiac medications in history.

Meanwhile, a New Drug Application (NDA) for another one of Ascentage Pharma’s key drug candidates, the novel Bcl-2 selective inhibitor lisaftoclax (APG-2575), has already been accepted and granted the ...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that Quebec has become the first ...

DelveInsight's Interferons Market Insights report provides the current and forecast market analysis, individual leading ...

With global cancer incidence rising and a strong clinical pipeline exploring combination therapies, the XPOVIO addressable market is expandin ...

Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal ...

AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for ...